About this Research Topic
Patients who suffered with COVID 19 along with the fungal infection had a high risk of severe illness and this lead to many deaths. SARS-CoV-2 virus damages the lung tissues and alveolo-interstitial lesions which puts the COVID-19 infected person prone to getting invasive fungal infections and also, in the case of the patients in Intensive Care Unit (ICU), they are very prone to these fungal diseases. In this pandemic people has suffered with different fungal infections like Candida auris pathogenesis along with COVID. Fungal species are responsible for many infections in human. For instance, Mucarmycosin spp; affects the sinuses, brain or lungs and therefore can be quite common in people suffering or recovering from COVID-19 and Candida spp; it causes fungal pneumonias, were majorly responsible. when antifungal drugs are used improperly Resistance can also develop over time.
Due to association with a very high mortality rate by invasive fungal infections during COVID 19, the researchers must put much emphasis on high index of suspicion, early diagnosis Proper Biomarkers should be developed for the early diagnosis, and appropriate management for patient survival. It is essential to assess the risk factors for SARS-CoV-2–associated pulmonary Candidiasis (Candia Auris) and the types of invasive mycosis to provide appropriate individualized treatment. Additional investigation is needed to understand the role of opportunistic infections in COVID-19 patients. Healthcare-associated infections (HAIs) should also be considered seriously which have acute risk factors linked to COVID-19 care, including medicines that suppress the immune system. We should better evaluate the incidence and the dynamic of fungal infection in the course of COVID-19 and propose an efficient syndromic molecular approach for fungal respiratory infection during ARDS that can be shared with all hospitals receiving COVID-19 patients.
Due to association with a very high mortality rate by invasive fungal infections during COVID 19, the researchers must put much emphasis on high index of suspicion, early diagnosis Proper Biomarkers should be developed for the early diagnosis, and appropriate management for patient survival. It is essential to assess the risk factors for SARS-CoV-2–associated pulmonary Candidiasis (Candia Auris) and the types of invasive mycosis to provide appropriate individualized treatment. Additional investigation is needed to understand the role of opportunistic infections in COVID-19 patients. Healthcare-associated infections (HAIs) should also be considered seriously which have acute risk factors linked to COVID-19 care, including medicines that suppress the immune system. We should better evaluate the incidence and the dynamic of fungal infection in the course of COVID-19 and propose an efficient syndromic molecular approach for fungal respiratory infection during ARDS that can be shared with all hospitals receiving COVID-19 patients.
Keywords: SARS-CoV-2, COVID19, fungal infections, Candida
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
